About Probable RNA-binding protein 23
Probable RNA-binding protein 23 (RBM23) is a protein
from Homo sapiens identified by UniProt accession
Q86U06, 439 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Target properties
| Protein name | Probable RNA-binding protein 23 |
| UniProt accession | Q86U06 |
| Gene | RBM23 |
| Organism | Homo sapiens |
| Length | 439 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (25)
Diseases linked to this target (Open Targets).
- self reported educational attainment · score 0.19
- mathematical ability · score 0.19
- intelligence · score 0.17
- FEV/FVC ratio · score 0.16
- cup-to-disc ratio measurement · score 0.15
- blood phosphate measurement · score 0.15
- systolic blood pressure · score 0.14
- eosinophil count · score 0.14
- schizophrenia · score 0.13
- brain measurement · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86U06-F1 | alphafold | PREDICTED | 63.90 | — |
Amino-acid sequence (439 residues)
MASDDFDIVI EAMLEAPYKK EEDEQQRKEV KKDYPSNTTS STSNSGNETS GSSTIGETSK KKRSRSHNKS RDRKRSRSRD RDRYRRRNSR SRSPGRQCRH RSRSWDRRHG SESRSRDHRR EDRVHYRSPP LATGYRYGHS KSPHFREKSP VREPVDNLSP EERDARTVFC MQLAARIRPR DLEDFFSAVG KVRDVRIISD RNSRRSKGIA YVEFCEIQSV PLAIGLTGQR LLGVPIIVQA SQAEKNRLAA MANNLQKGNG GPMRLYVGSL HFNITEDMLR GIFEPFGKID NIVLMKDSDT GRSKGYGFIT FSDSECARRA LEQLNGFELA GRPMRVGHVT ERLDGGTDIT FPDGDQELDL GSAGGRFQLM AKLAEGAGIQ LPSTAAAAAA AAAQAAALQL NGAVPLGALN PAALTALSPA LNLASQCFQL SSLFTPQTM
Explore Probable RNA-binding protein 23 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets